Identitet i podaci za kontakt voditelja obrade podataka Ova pravila o privatnosti primjenjuju se na sve osobne podatke koje obrauje Sensilab d.o.o., sa sjeditem na adresi Verovkova 55a, 1000 Ljubljana, Slovenija, matini broj drutva 2113732000, i Vision Healthcare Group, sa svojim registriranim sjeditem Grote Markt 41, 8500 Kortrijk, Belgija, matini broj drutva BE 0685.849.188, koji djeluju kao zajedniki voditelji obrade u skladu s GDPR-om (u daljnjem tekstu Voditelj obrade podataka)
1 Introduction According to the International Diabetes Federation, the global population with diabetes reached 537 million by 2021, with 90% of cases attributed to type 2 diabetes (T2DM) ( In recent years, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained attention not only for their role in glycemic control in T2DM but also for their potential in weight management
For patients already taking GLP-1 medications, there is no need for alarm
Below are some common reasons that could contribute to a lack of weight loss while on semaglutide, as noted by Chicago Arthritis and Regenerative Medicine: Wrong Dosage: Taking an incorrect dosage may hinder weight loss efforts
Table 2 provides an overview of locally acting (within the GI tract) and systemic oral peptide therapeutics that have been approved by the US Food and Drug Administration
